Aviron Says Flu Drug Won't Be as Late as Feared
Biotech company Aviron (AVIR) said Monday it is confident it won't have to conduct additional clinical trials for its flu vaccine before getting the treatment approved, based on feedback from the Food and Drug Administration.
On Friday, the FDA sent Aviron a "complete review letter," which detailed the steps required to get the experimental FluMist nasal spray vaccine approved. Aviron said Monday that the FDA has "requested additional information and clarification regarding clinical and manufacturing data" to support FluMist's application.
Aviron added that it still needs to clarify some of the FDA's requests, and the company did not predict how long it will take to respond to the FDA's questions, or how long regulators will take to review the new information.
But Aviron should be able to get FluMist to market in time for the 2002-2003 flu season. If it does, it will be one year behind schedule. Hopes to have the vaccine ready this year were dashed on July 27, when an FDA advisory panel did not recommend the drug's approval because of safety concerns, despite finding FluMist effective.If the FDA had asked Aviron to conduct more tests, FluMist could have been delayed even further. Monday's announcement should provide some support for Aviron shares, which have lost half their value since the July 27 setback. Aviron closed Friday at $22.39 per share. If approved, FluMist would be the first flu vaccine taken as a nasal spray by healthy adults and children. The drug will be co-marketed by American Home Products (AHP).
Select the service that is right for you!COMPARE ALL SERVICES
Jim Cramer and Stephanie Link actively manage a real portfolio and reveal their money management tactics while giving advanced notice before every trade.
- $2.5+ million portfolio
- Large-cap and dividend focus
- Intraday trade alerts from Cramer
- Weekly roundups
Access the tool that DOMINATES the Russell 2000 and the S&P 500.
- Buy, hold, or sell recommendations for over 4,300 stocks
- Unlimited research reports on your favorite stocks
- A custom stock screener
- Upgrade/downgrade alerts
Jim Cramer's protege, David Peltier, identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.
- Diversified model portfolio of dividend stocks
- Alerts when market news affect the portfolio
- Bi-weekly updates with exact steps to take - BUY, HOLD, SELL
All of Real Money, plus 15 more of Wall Street's sharpest minds delivering actionable trading ideas, a comprehensive look at the market, and fundamental and technical analysis.
- Real Money + Doug Kass Plus 15 more Wall Street Pros
- Intraday commentary & news
- Ultra-actionable trading ideas
Our options trading pros provide daily market commentary and over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.
- 100+ monthly options trading ideas
- Actionable options commentary & news
- Real-time trading community
- Options TV